Previous
Previous

UK consensus recommendations for clinical management of cancer risk for women with germline pathogenic variants in cancer predisposition genes: RAD51C, RAD51D, BRIP1 and PALB2

Next
Next

Clinical practice guidelines for the diagnosis and surveillance of BAP1 tumour predisposition syndrome